About this data
What it is
The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
Who files it
The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
How current
We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
Terms
openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
Worth knowing
This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
Not to be confused with
Clinical trial updates: what sponsors report about their studies, not what the FDA decided.

All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.

FDA decisions per day, last 30 days

010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0
010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0

Brand-name drugs and biologics, with supplements Device clearances and approvals

By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.

Latest FDA decisions

Reset

Showing: ticker PFE · Everything

Latest FDA decisions
DecidedProductApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.FDA page
Nov 9, 2026DEFEROXAMINE MESYLATE
DEFEROXAMINE MESYLATE
PFE
Hospira
Generic (ANDA), supplement
Labeling
ANDA076019 ↗
Nov 6, 2026HYMPAVZI
MARSTACIMAB-HNCQ
PFE
Pfizer Inc
Biologic (BLA), supplement
Labeling
BLA761369 ↗
Oct 26, 2026TALZENNA
TALAZOPARIB TOSYLATE
PFE
Pfizer
New drug (NDA), supplement
Efficacy
NDA217439 ↗
Oct 26, 2026TALZENNA
TALAZOPARIB TOSYLATE
PFE
Pfizer
New drug (NDA), supplement
Efficacy
NDA211651 ↗
Oct 21, 2026LINEZOLID, ZYVOX
LINEZOLID
PFE
Pfizer
New drug (NDA), supplement
Labeling
NDA021132 ↗
Letter or label ↗
Oct 21, 2026ZYVOX
LINEZOLID
PFE
Pfizer
New drug (NDA), supplement
Labeling
NDA021131 ↗
Letter or label ↗
Oct 21, 2026ZYVOX
LINEZOLID
PFE
Pfizer
New drug (NDA), supplement
Labeling
NDA021130 ↗
Letter or label ↗
Oct 15, 2026METHOTREXATE
METHOTREXATE SODIUM
PFE
Hospira
New drug (NDA), supplement
Labeling
NDA011719 ↗
Oct 14, 2026AZULFIDINE EN-TABS, SULFASALAZINE, AZULFIDINE
SULFASALAZINE
PFE
Pfizer
New drug (NDA), supplement
Labeling
NDA007073 ↗
Oct 7, 2026TUKYSA
TUCATINIB
PFE
Seagen
New drug (NDA), supplement
Efficacy
NDA213411 ↗
Sep 28, 2026RUXIENCE
RITUXIMAB-PVVR
PFE
Pfizer Inc
Biologic (BLA), supplement
BIOSIMILAR
BLA761103 ↗
Sep 24, 2026BUTORPHANOL TARTRATE PRESERVATIVE FREE
BUTORPHANOL TARTRATE
PFE
Hospira
Generic (ANDA), supplement
Labeling
ANDA074626 ↗
Sep 16, 2026XELJANZ
TOFACITINIB CITRATE
PFE
Pfizer
New drug (NDA), supplement
Labeling
NDA213082 ↗
Letter or label ↗
Sep 16, 2026XELJANZ XR
TOFACITINIB CITRATE
PFE
Pfizer
New drug (NDA), supplement
Labeling
NDA208246 ↗
Letter or label ↗
Sep 2, 2026CIBINQO
ABROCITINIB
PFE
Pfizer
New drug (NDA), supplement
Labeling
NDA213871 ↗
Sep 1, 2026CLEOCIN HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDE
PFE
Pfizer
New drug (NDA), supplement
Labeling
NDA050162 ↗
Aug 17, 2026ZAVZPRET
ZAVEGEPANT HYDROCHLORIDE
PFE
Pfizer
New drug (NDA), supplement
Labeling
NDA216386 ↗
Aug 3, 2026CYTARABINE
CYTARABINE
PFE
Hospira
Generic (ANDA), supplement
Labeling
ANDA075383 ↗
Aug 3, 2026CYTARABINE
CYTARABINE
PFE
Hospira
Generic (ANDA), supplement
Labeling
ANDA072945 ↗
Aug 3, 2026CYTARABINE
CYTARABINE
PFE
Hospira
Generic (ANDA), supplement
Labeling
ANDA072168 ↗
Jul 29, 2026CYTARABINE
CYTARABINE
PFE
Hospira
Generic (ANDA), supplement
Labeling
ANDA071868 ↗
Jul 13, 2026ZITHROMAX
AZITHROMYCIN
PFE
Pfizer
New drug (NDA), supplement
Labeling
NDA050784 ↗
Letter or label ↗
Jul 13, 2026ZITHROMAX
AZITHROMYCIN
PFE
Pfizer
New drug (NDA), supplement
Labeling
NDA050733 ↗
Jul 13, 2026ZITHROMAX
AZITHROMYCIN
PFE
Pfizer
New drug (NDA), supplement
Labeling
NDA050730 ↗
Letter or label ↗
Jul 13, 2026ZITHROMAX
AZITHROMYCIN
PFE
Pfizer
New drug (NDA), supplement
Labeling
NDA050711 ↗
Letter or label ↗
Jul 13, 2026ZITHROMAX
AZITHROMYCIN
PFE
Pfizer
New drug (NDA), supplement
Labeling
NDA050710 ↗
Letter or label ↗
Jul 13, 2026ZITHROMAX
AZITHROMYCIN
PFE
Pfizer
New drug (NDA), supplement
Labeling
NDA050670 ↗
Letter or label ↗
Jul 13, 2026HEPARIN SODIUM
HEPARIN SODIUM
PFE
Hospira Inc
Generic (ANDA), supplement
Labeling
ANDA090571 ↗
Jul 9, 2026HEPARIN SODIUM
HEPARIN SODIUM
PFE
Hospira
Generic (ANDA), supplement
Labeling
ANDA089522 ↗
Jul 9, 2026HEPARIN SODIUM
HEPARIN SODIUM
PFE
Hospira
Generic (ANDA), supplement
Labeling
ANDA088100 ↗
Jun 30, 2026LITFULO
RITLECITINIB TOSYLATE
PFE
Pfizer
New drug (NDA), supplement
Labeling
NDA215830 ↗
Jun 30, 2026CIBINQO
ABROCITINIB
PFE
Pfizer
New drug (NDA), supplement
Labeling
NDA213871 ↗
Jun 30, 2026XELJANZ
TOFACITINIB CITRATE
PFE
Pfizer
New drug (NDA), supplement
Labeling
NDA213082 ↗
Jun 30, 2026XELJANZ XR
TOFACITINIB CITRATE
PFE
Pfizer
New drug (NDA), supplement
Labeling
NDA208246 ↗
Jun 25, 2026SUFENTANIL CITRATE
SUFENTANIL CITRATE
PFE
Hospira
Generic (ANDA), supplement
Labeling
ANDA074534 ↗
Jun 24, 2026IBRANCE
PALBOCICLIB
PFE
Pfizer
New drug (NDA), supplement
Efficacy
NDA212436 ↗
Jun 24, 2026IBRANCE
PALBOCICLIB
PFE
Pfizer
New drug (NDA), supplement
Efficacy
NDA207103 ↗
Jun 9, 2026LINEZOLID
LINEZOLID
PFE
Hospira
New drug (NDA), supplement
Labeling
NDA206473 ↗
Jun 9, 2026LINEZOLID, ZYVOX
LINEZOLID
PFE
Pfizer
New drug (NDA), supplement
Labeling
NDA021132 ↗
Letter or label ↗
Jun 9, 2026ZYVOX
LINEZOLID
PFE
Pfizer
New drug (NDA), supplement
Labeling
NDA021131 ↗
Letter or label ↗
Jun 9, 2026ZYVOX
LINEZOLID
PFE
Pfizer
New drug (NDA), supplement
Labeling
NDA021130 ↗
Letter or label ↗
Jun 5, 2026HYMPAVZI
MARSTACIMAB-HNCQ
PFE
Pfizer Inc
Biologic (BLA), supplement
Efficacy
BLA761369 ↗
Jun 5, 2026LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE
PFE
Hospira
Generic (ANDA), supplement
Labeling
ANDA040078 ↗
May 21, 2026NYVEPRIA
PEGFILGRASTIM-APGF
PFE
Hospira Inc
Biologic (BLA), supplement
Labeling
BLA761111 ↗
May 21, 2026CLEOCIN PEDIATRIC
CLINDAMYCIN PALMITATE HYDROCHLORIDE
PFE
Pfizer
Generic (ANDA), supplement
Labeling
ANDA062644 ↗
May 21, 2026CLEOCIN PEDIATRIC
CLINDAMYCIN PALMITATE HYDROCHLORIDE
PFE
Pfizer
Generic (ANDA), supplement
Labeling
ANDA062644 ↗
May 21, 2026CLEOCIN PEDIATRIC
CLINDAMYCIN PALMITATE HYDROCHLORIDE
PFE
Pfizer
Generic (ANDA), supplement
Labeling
ANDA062644 ↗
May 8, 2026NURTEC ODT
RIMEGEPANT SULFATE
PFE
Pfizer
New drug (NDA), supplement
Labeling
NDA212728 ↗
May 1, 2026PRECEDEX
DEXMEDETOMIDINE HYDROCHLORIDE
PFE
Hospira
New drug (NDA), supplement
Labeling
NDA021038 ↗
Apr 29, 2026NGENLA
SOMATROGON-GHLA
PFE
Pfizer Ireland Pharmaceuticals
Biologic (BLA), supplement
Labeling
BLA761184 ↗

The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 6:00 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates